Lb Pharmaceuticals INC

LB Pharmaceuticals announced accelerated topline data for its LB-102 schizophrenia trial, plans pipeline expansion, and secured $150 million in funding.

LB Pharmaceuticals Inc. announced a $150 million private placement of common stock and pre-funded warrants to institutional investors to fund pipeline expansion and general corporate purposes.

LB Pharmaceuticals announced accelerated timing for topline results from its Phase 3 NOVA-2 clinical trial for schizophrenia drug LB-102, now expected in the first half of 2027.

LB Pharmaceuticals Chief Medical Officer Dr. Anna Eramo will resign effective June 15, 2026, transitioning to a consulting role through September 15, 2026.

LB Pharmaceuticals Inc. reports final voting results from its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

LB Pharmaceuticals announced Q1 2026 financial results, highlighting progress in late-stage clinical trials for LB-102 and securing $100 million in private placement funding.

LB Pharmaceuticals Inc. reported a substantial increase in research and development expenses and a widening net loss for the second quarter of 2026, driven by ongoing clinical trials for its lead product candidate, LB-102.

LB Pharmaceuticals Inc. announced its first-quarter 2026 financial results, highlighting progress in its clinical development programs for LB-102 and a strong cash position.

LB Pharmaceuticals Inc. successfully completed its initial public offering, raising $302.3 million net, significantly bolstering its cash position to fund operations into Q2 2028 while progressing its lead drug candidate, LB-102, into Phase 3 for schizophrenia and Phase 2 for bipolar depression.

LB Pharmaceuticals Inc. reports significant progress in its clinical pipeline, with lead candidate LB-102 entering Phase 3 for acute schizophrenia and Phase 2 for bipolar depression, alongside a recent $100 million capital raise.

Deep Track Biotechnology Master Fund, Ltd. and 2 others reported changes in beneficial ownership of Lb Pharmaceuticals Inc common stock on July 30, 2026.

Director Robert Ruffolo was granted 10,000 stock options in LB Pharmaceuticals Inc. with an exercise price of $27.95.

Director Ran Nussbaum was granted 10,000 stock options in LB Pharmaceuticals Inc. with an exercise price of $27.95.

Director Rebecca Luse was granted 10,000 stock options in LB Pharmaceuticals Inc. with an exercise price of $27.95.

Director Robert A. Lenz of LB Pharmaceuticals Inc. was granted 12,500 stock options as part of the company's director compensation policy.

Director Rekha Hemrajani was granted 10,000 stock options in LB Pharmaceuticals Inc. as part of a standard equity compensation arrangement.

LB Pharmaceuticals Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 3, 2026, to elect directors and ratify auditor appointments.

LB Pharmaceuticals has filed a registration statement for the resale of up to 4,778,491 shares of common stock by existing selling stockholders.

LB Pharmaceuticals Inc. filed an S-1MEF to register an additional $21.1 million in common stock for its public offering, bringing the total offering to approximately $327.8 million, though auditors noted a going concern.

LB Pharmaceuticals Inc. is launching an initial public offering of 16,666,667 shares to raise capital for the clinical development of its lead candidate, LB-102, for schizophrenia and bipolar depression.

LB Pharmaceuticals Inc. is launching its initial public offering to fund the development of LB-102, a Phase 3-ready drug for schizophrenia and bipolar depression, following positive Phase 2 results.

Deep Track Capital and its affiliates have increased their beneficial ownership in LB Pharmaceuticals Inc to 11.7% following a private placement of common stock and pre-funded warrants.

Investment group Pontifax, through its various entities and managing partners, has disclosed a 6.3% beneficial ownership stake in LB Pharmaceuticals Inc. following the company's IPO.

Deep Track Capital and its affiliated funds have collectively acquired a 14.9% beneficial ownership stake in LB Pharmaceuticals Inc. following its IPO.

JPMorgan Chase & Co. has reported beneficial ownership of 5.2% of LB Pharmaceuticals Inc.'s common stock as of June 30, 2026.

TCG Crossover Fund II, L.P. and related entities have filed an amendment reporting a 6.4% beneficial ownership stake in LB Pharmaceuticals Inc.

Commodore Capital LP and its principals have reported a 6.8% beneficial ownership stake in LB Pharmaceuticals Inc. via a Schedule 13G filing.

Caligan Partners LP and David Johnson have disclosed a beneficial ownership of 5.0% in LB Pharmaceuticals Inc., holding 1,438,070 shares.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting beneficial ownership of 4.9% of LB Pharmaceuticals Inc. common stock as of March 31, 2026.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in LB PHARMACEUTICALS INC, holding 1,277,776 shares of common stock.